Nafziger AN - Search Results

1

S-Warfarin Limited Sampling Models to Estimate Area Under the Concentration Versus Time Curve for Cytochrome P450 2C9 Baseline Activity and After Induction.

Chang AT, Bertino JS Jr, Nafziger AN, Kashuba AD, Turpault S, Lewis LD, Ma JD. Chang AT, et al. Among authors: nafziger an. Ther Drug Monit. 2016 Jun;38(3):383-7. doi: 10.1097/FTD.0000000000000277. Ther Drug Monit. 2016. PMID: 26818625

2

Limitations of S-warfarin truncated area under the concentration-time curve to predict cytochrome P450 2c9 activity.

Wu JC, Nafziger AN, Bertino JS Jr, Ma JD. Wu JC, et al. Among authors: nafziger an. Drug Metab Lett. 2012 Jun 1;6(2):94-101. doi: 10.2174/187231212804096736. Drug Metab Lett. 2012. PMID: 22594566

3

Midazolam Single Time Point Concentrations to Estimate Exposure and Cytochrome P450 (CYP) 3A Constitutive Activity Utilizing Limited Sampling Strategy With a Population Pharmacokinetic Approach.

Yang J, Patel M, Nikanjam M, Capparelli EV, Tsunoda SM, Greenberg HE, Penzak SR, Aubrey Stoch S, Bertino JS Jr, Nafziger AN, Ma JD. Yang J, et al. Among authors: nafziger an. J Clin Pharmacol. 2018 Sep;58(9):1205-1213. doi: 10.1002/jcph.1125. Epub 2018 Apr 17. J Clin Pharmacol. 2018. PMID: 29663428

4

Evaluation of Omeprazole Limited Sampling Strategies to Estimate Constitutive Cytochrome P450 2C19 Activity in Healthy Adults.

Lin S, Nikanjam M, Capparelli EV, Allegrini A, Pavone D, Yim DS, Hammami MM, Bertino JS Jr, Nafziger AN, Park YS, Kang JS, Yin OQ, Ma JD. Lin S, et al. Among authors: nafziger an. Ther Drug Monit. 2018 Dec;40(6):754-758. doi: 10.1097/FTD.0000000000000554. Ther Drug Monit. 2018. PMID: 30045358 Free PMC article.

5

Midazolam Limited Sampling Strategy With a Population Pharmacokinetic Approach to Simultaneously Estimate Cytochrome P450 (CYP) 3A Constitutive, Inhibition, and Induction/Activation Conditions in Healthy Adults.

Yang J, Nikanjam M, Capparelli EV, Tsunoda SM, Greenberg HE, Penzak SR, Stoch SA, Bertino JS Jr, Nafziger AN, Ma JD. Yang J, et al. Among authors: nafziger an. J Clin Pharmacol. 2019 Nov;59(11):1495-1504. doi: 10.1002/jcph.1440. Epub 2019 May 3. J Clin Pharmacol. 2019. PMID: 31051051

6

S-warfarin limited sampling strategy with a population pharmacokinetic approach to estimate exposure and cytochrome P450 (CYP) 2C9 activity in healthy adults.

Tran L, Nikanjam M, Capparelli EV, Bertino JS Jr, Nafziger AN, Kashuba ADM, Turpault S, Ma JD. Tran L, et al. Among authors: nafziger an. Eur J Clin Pharmacol. 2021 Sep;77(9):1349-1356. doi: 10.1007/s00228-021-03123-y. Epub 2021 Mar 23. Eur J Clin Pharmacol. 2021. PMID: 33754183

7

Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques.

Kim JS, Nafziger AN, Tsunoda SM, Choo EE, Streetman DS, Kashuba AD, Kulawy RW, Beck DJ, Rocci ML Jr, Wilkinson GR, Greenblatt DJ, Bertino JS Jr. Kim JS, et al. Among authors: nafziger an. J Clin Pharmacol. 2002 Apr;42(4):376-82. J Clin Pharmacol. 2002. PMID: 11936561

8

Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs.

Rogers JF, Nafziger AN, Bertino JS Jr. Rogers JF, et al. Among authors: nafziger an. Am J Med. 2002 Dec 15;113(9):746-50. doi: 10.1016/s0002-9343(02)01363-3. Am J Med. 2002. PMID: 12517365 Review.

9

Cisapride: a potential model substrate to assess cytochrome P4503A4 activity in vivo.

Lowry JA, Kearns GL, Abdel-Rahman SM, Nafziger AN, Khan IS, Kashuba AD, Schuetz EG, Bertino JS Jr, van den Anker JN, Leeder JS. Lowry JA, et al. Among authors: nafziger an. Clin Pharmacol Ther. 2003 Mar;73(3):209-22. doi: 10.1067/mcp.2003.29. Clin Pharmacol Ther. 2003. PMID: 12621386 Clinical Trial.

10

Limited sampling strategy of S-warfarin concentrations, but not warfarin S/R ratios, accurately predicts S-warfarin AUC during baseline and inhibition in CYP2C9 extensive metabolizers.

Ma JD, Nafziger AN, Kashuba AD, Kim MJ, Gaedigk A, Rowland E, Kim JS, Bertino JS Jr. Ma JD, et al. Among authors: nafziger an. J Clin Pharmacol. 2004 Jun;44(6):570-6. doi: 10.1177/0091270004265366. J Clin Pharmacol. 2004. PMID: 15145963

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

121 results

Search Page

Filters